InDex Pharmaceuticals Holding (OM:INDEX) - Aktienkurs, Nachrichten und Analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

INDEX Aktienübersicht

InDex Pharmaceuticals Holding AB (publ) beschäftigt sich mit der Erforschung und Entwicklung von Arzneimitteln für immunologische Krankheiten.

Über das Unternehmen

INDEX grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Die Erträge sind in den letzten 5 Jahren um 2.7% pro Jahr gestiegen.

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 48.5% pro Jahr sinken.

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Hat keine nennenswerte Marktkapitalisierung (SEK270M)

InDex Pharmaceuticals Holding AB (publ) Wettbewerber

ODI Pharma

NGM:ODI

SEK 70.0m

Ziccum

OM:ZICC

SEK 52.2m

Corline Biomedical

OM:CLBIO

SEK 170.2m

AcuCort

NGM:ACUC

SEK 121.6m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für InDex Pharmaceuticals Holding
Historische Aktienkurse
Aktueller Aktienkurs	SEK 0.55
52-Wochen-Hoch	SEK 0.93
52-Wochen-Tief	SEK 0.20
Beta	-0.21
11 Monat Veränderung	35.15%
3 Monate Veränderung	88.28%
1 Jahr Veränderung	-4.55%
33 Jahre Veränderung	-63.84%
5 Jahre Veränderung	-93.87%
Veränderung seit IPO	-92.20%

Aktuelle Nachrichten und Updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21

Aktionärsrenditen

	INDEX	SE Pharmaceuticals	SE Markt
7D	1.1%	-3.5%	1.9%
1Y	-4.5%	65.6%	24.3%

Rendite im Vergleich zur Industrie: INDEX unter dem Niveau der Branche Swedish Pharmaceuticals, die im vergangenen Jahr eine Rendite von 55.4% erzielte.

Rendite vs. Markt: INDEX hinter dem Markt Swedish zurück, der im vergangenen Jahr eine Rendite von 16.4 erzielte.

Preisvolatilität

Is INDEX's price volatile compared to industry and market?
INDEX volatility
INDEX Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.7%
10% least volatile stocks in SE Market	3.2%

Stabiler Aktienkurs: INDEXDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: INDEXDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2000	4	Jenny Sundqvist	www.indexpharma.com

InDex Pharmaceuticals Holding AB (publ) beschäftigt sich mit der Erforschung und Entwicklung von Arzneimitteln für immunologische Krankheiten. Das Unternehmen wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Solna, Schweden.

InDex Pharmaceuticals Holding AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von InDex Pharmaceuticals Holding im Vergleich zum Marktanteil des Unternehmens?
INDEX grundlegende Statistiken
Marktanteil	SEK 286.59m
Gewinn(TTM)	-SEK 56.48m
Umsatz(TTM)	SEK 108.34m

2.7x

Kurs-Umsatz-Verhältnis

-5.1x

Kurs-Gewinn-Verhältnis

Ist INDEX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
INDEX Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 108.34m
Kosten der Einnahmen	SEK 4.03m
Bruttogewinn	SEK 104.31m
Sonstige Ausgaben	SEK 160.79m
Umsatz	-SEK 56.48m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Aug 20, 2024

Gewinn per Aktie (EPS)	-0.11
Bruttomarge	96.28%
Nettogewinnspanne	-52.13%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich INDEX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company is no longer active

INDEX Aktienübersicht

Belohnungen

Risikoanalyse

InDex Pharmaceuticals Holding AB (publ) Wettbewerber

NGM:ODI

SEK 70.0m

OM:ZICC

SEK 52.2m

OM:CLBIO

SEK 170.2m

NGM:ACUC

SEK 121.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

InDex Pharmaceuticals Holding AB (publ) Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024

InDex Pharmaceuticals Holding AB (publ) Discontinues the Development of Cobitolimod

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

InDex Pharmaceuticals Holding AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.006 loss in 3Q 2022)

New major risk - Share price stability

InDex Pharmaceuticals Holding AB (publ) Discontinues Cobitolimod Phase III Program

InDex Pharmaceuticals Holding AB (publ) Announces Composition of the Nomination Committee

InDex Pharmaceuticals Holding AB (Publ) Receives New Patent for Cobitolimod in South Korea

InDex Pharmaceuticals Holding AB (publ) Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude

InDex Pharmaceuticals Holding AB (publ) Announces Positive Results from the Pharmacokinetic (PK) Study

InDex Pharmaceuticals Holding AB (publ) Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Deputy CEO & Chief Financial Officer recently bought kr66k worth of stock

Price target decreased by 31% to kr1.90

InDex Pharmaceuticals Holding AB (publ) Updates the Timeline of the Phase III Study CONCLUDE with cobitolimod

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Final Results on Apr 12, 2023

InDex Pharmaceuticals Holding AB (publ) to Report Q1, 2023 Results on May 24, 2023

Third quarter 2022 earnings released: kr0.006 loss per share (vs kr0.05 loss in 3Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

InDex Pharmaceuticals Holding AB (publ) Appoints Jenny Sundqvist as New CEO, Effective January 1, 2023

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Successful Interactions with the Pmda for the Clinical Development of Cobitolimod in Japan

InDex Pharmaceuticals Holding AB (publ) Announces Board Appointments

First quarter 2022 earnings released: kr0.04 loss per share (vs kr0.02 loss in 1Q 2021)

InDex Pharmaceuticals Strengthens the Organization with Eva Arlander as Chief Development Officer and Announces Changes in the Composition of the Management Team

Full year 2021 earnings released: kr0.21 loss per share (vs kr0.24 loss in FY 2020)

InDex Pharmaceuticals Holding AB (publ) Announces CEO Changes

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Full year 2021 earnings: EPS misses analyst expectations

InDex Pharmaceuticals Holding AB (publ) Announces Resignation of Pernilla Sandwall as Chief Operating Officer

InDex Pharmaceuticals Enrols First Patient in the Pk Study with Cobitolimod

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

InDex Pharmaceuticals Holding AB (publ) Enrolls First Patient in Phase III Study CONCLUDE with Cobitolimod in Ulcerative Colitis

Second quarter 2021 earnings released

InDex Pharmaceuticals Receives FDA Clearance to start the Phase III Study CONCLUDE with Cobitolimod

InDex Pharmaceuticals Holding AB (publ) to Conduct Clinical Pharmacokinetic Study (PK Study) with Cobitolimod in Sweden

InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III study CONCLUDE with Cobitolimod

Independent Director Stig Pedersen has left the company

Independent Director Yilmaz Mahshid has left the company

InDex Pharmaceuticals Holding AB (publ) Announces Patient Recruitment for Phase III Study CONCLUDE is Planned to Initiate after Summer

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding AB (Publ) Announces Changes in the Nomination Committee for the 2021 Annual General Meeting

Revenue in line with expectations

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 23, 2021

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

New 90-day low: kr3.88

Erträge & Einnahmen